Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial

Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Apr 8, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring the best way to help women who have experienced a nonviable pregnancy (meaning the fetus cannot survive) during the second trimester. The researchers are comparing two methods: giving mifepristone (a medication often used to help with pregnancy loss) at the same time as misoprostol (another medication used to induce labor) versus using misoprostol alone. The goal is to see if giving both medications together can reduce the time it takes for women to deliver, which is important to minimize potential risks to the mother's health.

To participate in this trial, women must be at least 18 years old, between 14 and 28 weeks pregnant with a single fetus, and have a nonviable pregnancy. They should also need to start the labor process. Participants can expect to receive either both medications together or just misoprostol and will be monitored throughout the trial. This study is currently recruiting participants, and it aims to improve care for women experiencing pregnancy loss by finding the most effective way to induce labor in these challenging situations.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older
• • 14 and 28 weeks' gestation
• • Singleton gestation
• • Nonviable fetus (i.e. fetal demise or previable gestational age/weight or lethal fetal anomaly)
• • Requires induction of labor
• • If fetal cardiac motion, abortion being performed for medical emergency per MO laws and consents completed
• Exclusion Criteria:
• • Contraindication to mifepristone
• • Plan for surgical evacuation of uterus
• • Contraindication to vaginal delivery
• • Plan to initiate induction with any medication or device except misoprostol
• • Declines participation